Filing Flows › Companies › Prelude Therapeutics › Report card
Prelude Therapeutics earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate3 of 4 reports beat the EPS estimate
Prelude Therapeutics (PRLD) beat the analysts' EPS estimate in 3 of its last 4 reports (75%), by +22.8% on average. Next report: Nov 11, 2026, analysts expect EPS −$0.14.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | GAAP EPS | Revenue reported |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | −$0.18 | −$0.14 | +24.3% | −$0.14 | $5.7M |
| Q1 2026 | May 12, 2026 | −$0.27 | −$0.13 | +51.3% | −$0.13 | $4.6M |
| Q4 2025 | Mar 10, 2026 | −$0.18 | −$0.20 | -11.1% | — | $5.6M |
| Q3 2025 | Nov 12, 2025 | −$0.35 | −$0.26 | +26.8% | −$0.26 | $6.5M |
Estimates and reported EPS are the Street's adjusted figures; GAAP EPS is from the filing (SEC XBRL). Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Prelude Therapeutics: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.